EFFECT OF PIRIBEDIL ON PLASMA PROLACTIN LEVELS IN WOMEN WITH PUERPERAL OR PATHOLOGICAL HYPERPROLACTINAEMIA

Publisher Website
Google Scholar
Abstract
In women with physiological puerperal hyperprolactinemia, acute administration of piribedil (100mg orally) a drug which stimulates dopamine receptor sites, was as effective as that of 2-Br-.alpha.-ergocryptine (CB 154, 5 mg orally) in suppressing elevated baseline plasma prolactin (PRL) levels. In 2 hyperprolactinemic women with radiological evidence of an intrasellar pituitary tumor, piribedil (100 mg orally) in contrast to CB 154 (5 mg orally) failed to modify plasma PRL levels, whereas in 3 other hyperprolactinemic women with no radiological evidence of pituitary tumor, its effect was not clear-cut, even though it could not be differentiated from that of CB 154. These results indicated that piribedil is an effective suppressor of plasma PRL levels in the human and suggest that its action is more evident in puerperal than in pathological hyperprolactinemia.

This publication has 0 references indexed in Scilit: